Initial Public Offering

Celltrion Healthcare $890m IPO to up biosimilar inventory and broaden portfolio

04-Aug-2017 By Dan Stanton

Celltrion Healthcare will purchase more biosimilars from biomanufacturing partner Celltrion Inc. and expand its distribution network after raising one trillion Won ($888m) in an IPO.

Sun shines on CMO Samsung Biologics to make its psoriasis mAb candidate

04-Jul-2017 By Dan Stanton

Samsung Biologics will make Sun Pharma’s psoriasis monoclonal antibody candidate Tildrakizumab in a deal worth $55.5m.

Kite public offering looks to raise $350m for CAR T cell therapy support

07-Mar-2017 By Staff Reporter

Kite Pharma has announced a public offering to support commercialisation of its lead CAR-based therapy, axicabtagene ciloleucel.

Wuxi Biologics files IPO prospectus aiming to be gateway to China

25-Jan-2017 By Gareth Macdonald

Wuxi Biologics has confirmed its intention to go public in an IPO application that reveals the contracter has seen revenue double and profits increase three-fold since 2014. 

Biogen eyes Regenxbio delivery tech for candidate occular gene therapies

17-May-2016 By Gareth Macdonald

Biogen has licensed rights use a gene therapy delivery technology from developer Regenxbio.

Samsung Biologics: IPO will support ambition to be top bio-CMO

29-Apr-2016 By Dan Stanton

Samsung Biologics says going public will help fulfil its ambition to become the world’s largest biologics contract manufacturing organisation (CMO).

Bio-Finance Vision... Baxalta, Pall and more in glorious technicolour

10-Jul-2015 By Dan Stanton

We say hello to Baxalta, ask what's the latest in Danaher's $14bn bid for Pall, and look at the latest biotech IPOs in today's Bio-Finance Vision.

Abivax's IPO to fund HIV and hep B pipeline before potential Big Pharma deal

06-Jul-2015 By Dan Stanton

In France’s largest ever biotech IPO, Abivax has raised €58m ($64m) to continue developing its HIV and Hep B candidates.

Samsung Bioepis mulls NASDAQ IPO to raise cash for biosimilars

01-Jul-2015 By Gareth Macdonald

Samsung Bioepis is considering an IPO on the NASDAQ Stock Exchange to raise cash to fund the development of biosimilar products.

Biotech fund Flagship Ventures raises $537m for biggest round yet

27-Mar-2015 By Fiona BARRY

The venture capital fund that launched Acceleron, Moderna, and Bind Therapeutics has raised $537m (€493m) for another round of funding.

Pfenex focuses on biosimilars post IPO

02-Sep-2014 By Dan Stanton

Revenues from protein production will decline as Pfenex shifts attention to its biosimilar pipeline, the newly public company says.

'Tech platform spurred Lucentis biosimilar,' says Pfenex in $75m IPO

10-Jun-2014 By Dan Stanton

Pfenex has filed for an initial public offering to raise $75m to develop biosimilars using its protein producing Expression Technology platform.

Chinese service provider files $80m IPO to fund expansion

28-Feb-2012 By Nick Taylor

A Chinese company that offers drug development services using a network of 99 third-party vendors has filed an $80m IPO.

£6.6m fundraising for BioProgress

04-Dec-2003

UK encapsulation company BioProgress yesterday unveiled plans to
raise £6.6 million (€9.4m) through a placement of shares in order
to build a new pharmaceutical production plant.